The CaSR-positive allosteric modulator, cinacalcet, which enhances receptor sensitivity to extracellular calcium, has successfully reduced PTH and serum calcium in some NSHPT patients [15, 17]. This evidence concerns the gene CASR and neonatal severe primary hyperparathyroidism.